Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eiger Biopharma (EIGR)

Eiger Biopharma (EIGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 241,840
  • Shares Outstanding, K 29,243
  • Annual Sales, $ 0 K
  • Annual Income, $ -70,250 K
  • 60-Month Beta 1.50
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.41
Trade EIGR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.60
  • Number of Estimates 3
  • High Estimate -0.53
  • Low Estimate -0.68
  • Prior Year -0.76
  • Growth Rate Est. (year over year) +21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.67 +6.13%
on 09/28/20
11.31 -28.03%
on 08/31/20
-2.57 (-24.00%)
since 08/28/20
3-Month
7.67 +6.13%
on 09/28/20
12.66 -35.73%
on 08/10/20
-1.46 (-15.21%)
since 06/30/20
52-Week
4.55 +78.90%
on 03/16/20
15.82 -48.55%
on 12/26/19
-2.11 (-20.59%)
since 09/30/19

Most Recent Stories

More News
Eiger Down on Disappointing Results From Coronavirus Study

Eiger (EIGR) declines on disappointing study results on candidate, peginterferon lambda-1a (lambda), in outpatients with mild and uncomplicated COVID-19.

MRK : 82.95 (+1.28%)
BMY : 60.29 (+0.65%)
HZNP : 77.68 (-0.61%)
EIGR : 8.14 (-1.57%)
Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19

, Sept. 28, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced...

EIGR : 8.14 (-1.57%)
Implied Volatility Surging for Eiger BioPharmaceuticals (EIGR) Stock Options

Investors need to pay close attention to Eiger BioPharmaceuticals (EIGR) stock based on the movements in the options market lately.

EIGR : 8.14 (-1.57%)
Eiger Bio to Participate in September 2020 Investor Conferences

, /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management...

EIGR : 8.14 (-1.57%)
Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress™ 2020

, /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious rare and ultra-rare diseases, today...

EIGR : 8.14 (-1.57%)
Eiger BioPharmaceuticals (EIGR) Catches Eye: Stock Jumps 8.6%

Eiger BioPharmaceuticals (EIGR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

RGEN : 147.54 (-2.03%)
EIGR : 8.14 (-1.57%)
Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

, /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial...

EIGR : 8.14 (-1.57%)
Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences

, /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management...

EIGR : 8.14 (-1.57%)
Why Eiger BioPharmaceuticals (EIGR) Stock Might be a Great Pick

Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

EIGR : 8.14 (-1.57%)
Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020

, /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from...

EIGR : 8.14 (-1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.

See More

Key Turning Points

2nd Resistance Point 8.67
1st Resistance Point 8.40
Last Price 8.14
1st Support Level 7.97
2nd Support Level 7.81

See More

52-Week High 15.82
Fibonacci 61.8% 11.51
Fibonacci 50% 10.18
Fibonacci 38.2% 8.86
Last Price 8.14
52-Week Low 4.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar